Skip to main content
SpringerLink
Log in
Book cover

New Drugs in Cancer Chemotherapy pp 7–15Cite as

Preclinical Rationale and Phase I Clinical Trial of the Adriamycin Analog, AD 32

  • Conference paper

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 76))

Abstract

The preclinical and clinical data for the adriamycin analog (AD 32) will be reviewed and compared to adriamycin. Emphasis will be placed on demonstrated biologic differences that may make AD 32 the better compound for clinical use.

Supported in part by Contract N01-CM-53839 (Division of Cancer Treatment), and Public Health Service Grant CA-19118 from the National Cancer Institute

The authors wish to acknowledge the invaluable assistance of Ms. Carol McCormick tor her data management, and Ms. Martha J. Sack for manuscript preparation

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Billingham ME, Mason JW, Bristow MR, Daniels JR (1978) Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 62: 865–872

    PubMed  CAS  Google Scholar 

  2. Blum RH, Garnick MB, Israel M, Canellos GP, Henderson IC, Frei III E (to be published) Initial clinical evaluation of N-trifluoracetyladriamycin-14-valerate (AD 32), and adriamycin analog. Cancer Treat Rep 63

    Google Scholar 

  3. Bristow MR, Mason JW, Billingham ME, Daniels JR (1978) Duxorubicin cardiomyopathy: Evaluation by phonocardiography, endomyocardial biopsy and cardiac catheterization. Ann Intern Med 88:168–175

    PubMed  CAS  Google Scholar 

  4. Facchinetti T, Mantovani A, Cantoni L, Cantoni R, Salmona M (1978) Intercalation with DNA is a prerequisite for daunomycin, adriamycin and its congeners in inhibiting DNAase I. Chem Biol Interact 20:97–102

    Article  PubMed  CAS  Google Scholar 

  5. Frei III E, Luce JK, Middleman E (1972) Clinical trials of adriamycin. In: Carter SK, DiMarco A, Ghione M, Krakoff IH, Mathe G (eds) International symposium of adriamycin. Springer, Berlin Heidelberg New York, pp 153–160

    Chapter  Google Scholar 

  6. Garnick MB, Israel M, Pegg WJ, Blum RH, Smith E, Frei III E (1979) Hepatobiliary pharmacokinetics of AD 32 in man. Proc Am Assoc Cancer Res 20:206

    Google Scholar 

  7. Henderson IC, Billingham M, Israel M, Krishan A, Frei III E (1978) Comparative cardiotoxicity studies with adriamycin (ADR) and AD 32 in rabbits. Proc Am Assoc Cancer Res 19:158

    Google Scholar 

  8. Israel M, Garnick MB, Pegg WJ, Blum RH, Frei III E (1978) Preliminary pharmacology of AD 32 in man. Proc Am Assoc Cancer Res 19:160

    Google Scholar 

  9. Israel M, Modest EJ, Frei III E (1975) N-trifluoroacetyladriamycin-14-valerate, an analog with greater experimental antitumor activity and less toxicity than adriamycin. Cancer Res 35:1365–1368

    PubMed  CAS  Google Scholar 

  10. Israel M, Pegg WJ, Wilkinson PM, Garnick MB (1979) HPLC applications in the analysis of adriamycin and analogs in biological fluids. In: Hawk GL (ed) Biological-biomedical applications of liquid chromatography. Dekker, New York, pp 413–428

    Google Scholar 

  11. Israel M, Pegg WJ, Wilkinson PM (1978) Urinary anthracycline metabolites from mice treated with adriamycin and N-trifluoroacetyladriamycin-14-valerate. J Pharmacol Exp Ther 204:696–701

    PubMed  CAS  Google Scholar 

  12. Israel M, Wilkinson PM, Osteen RT (1978) Comparative pharmacology of adriamycin and N-trifluoroacetyladriamycin-14-valerate in the monkey. Int Cancer Congr (Abstr) 1:279

    Google Scholar 

  13. Israel M, Wilkinson PM, Pegg WJ, Frei III E (1978) Hepatobiliary metabolism and excretion of adriamycin and N-trifluoroacetyladriamycin-14-valerate in the rat. Cancer Res 38:365–370

    PubMed  CAS  Google Scholar 

  14. Krishan A, Dutt K, Israel M Personal communication

    Google Scholar 

  15. Krishan A, Ganapathi RN, Israel M (1978) Effect of adriamycin and analogs on the nuclear fluorescence of propidium iodide-stained cells. Cancer Res 38:3656–3662

    PubMed  CAS  Google Scholar 

  16. Krishan A, Israel M, Modest EJ, Frei III E (1976) Differences in cellular uptake and cytofluorescence of adriamycin and N-trifluoroacetyl-adriamycin-14-valerate. Cancer Res 36:2114–2116

    Google Scholar 

  17. Lazarus H, Yuan G, Tan E, Israel M (1978) Comparative inhibitory effects of adriamycin, AD 32, and related compounds on in vitro cell growth and macromolecular synthesis. Proc Am Assoc Cancer Res 19:159

    Google Scholar 

  18. Meriwether WD, Bachur NR (1972) Inhibition of DNA and RNA metabolism by daunorubicin and adriamycin in L-1210 mouse leukemia. Cancer Res 32:1137–1142

    PubMed  CAS  Google Scholar 

  19. Parker LM, Hirst M, Israel M (1978) N-trifluoroaeetyladriamycin-14-valerate: Additonal mouse antitumor and toxicity studies. Cancer Treat Rep 62:119–127

    PubMed  CAS  Google Scholar 

  20. Sengupta SK, Seshadri R, Modest EJ, Israel M (1976) Comparative DNA-binding studies with adriamycin (ADR), N-trifluoroacetyladriamycin-14-valerate (AD 32) and related compounds. Proc Am Assoc Cancer Res 17:109

    Google Scholar 

  21. Vecchi A, Cairo M, Mantovani A, Sironi M, Spreafico F (1978) Comparative antineoplastic activity of adriamycin and N-trifluoroacetyladriamycin-14-valerate. Cancer Treat Rep 62:111–117

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology and Pharmacology, Sidney Farber Cancer Institute, Havard Medical School, USA, Boston, MA, 02115

    R. H. Blum, M. B. Garnick, M. Israel, G. P. Panellos, I. C. Henderson & E. Frei III

Authors
  1. R. H. Blum
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. B. Garnick
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Israel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. P. Panellos
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. I. C. Henderson
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E. Frei III
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Northern California Cancer Program, 1801 Page Mill Road, Suite 200, Building B, Palo Alto, CA, 94304, USA

    Stephen K. Carter

  2. Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Kami-Ikebukuro 1-37-1, Toshima-ku, Tokyo 170, Japan

    Yoshi Sakurai

  3. Institute of Microbial Chemistry, 14-23 Kamiosaki 3-Chome, Shinagawa-ku, Tokyo 141, Japan

    Hamoa Umezawa

Rights and permissions

Reprints and permissions

Copyright information

© 1981 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Blum, R.H., Garnick, M.B., Israel, M., Panellos, G.P., Henderson, I.C., Frei, E. (1981). Preclinical Rationale and Phase I Clinical Trial of the Adriamycin Analog, AD 32. In: Carter, S.K., Sakurai, Y., Umezawa, H. (eds) New Drugs in Cancer Chemotherapy. Recent Results in Cancer Research, vol 76. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81565-2_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-81565-2_2

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-81567-6

  • Online ISBN: 978-3-642-81565-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation